

# SURVEY: Treatment of Excessive Daytime Sleepiness With Solriamfetol: Initiation, Titration, and Outcomes

Gregory Parks, PhD<sup>1</sup>; Lothar Burghaus, MD<sup>2</sup>;  
Graham M.L. Eglit, PhD<sup>1</sup>; Samantha Floam,  
DMD<sup>1</sup>; Yaroslav Winter, MD<sup>3</sup>

<sup>1</sup>Axsome Therapeutics, Inc., New York, New York, USA;  
<sup>2</sup>Department of Neurology, Hellig Geist-Hospital, Cologne,  
Germany; <sup>3</sup>Mainz Comprehensive Epilepsy and Sleep Medicine  
Center, Department of Neurology, Johannes Gutenberg-  
University, Mainz, Germany

## Objective

- This real-world study characterizes dosing and titration strategies among European physicians initiating solriamfetol, as well as treatment outcomes following initiation in patients with excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA)

## Conclusions

- This pooled analysis of SURVEY results shows that the majority of patients with narcolepsy and OSA were new to therapy; switching to solriamfetol was also common
- Clinically meaningful improvements in Epworth Sleepiness Scale (ESS) scores were observed with solriamfetol regardless of initiation strategy and across etiologies
  - Overall, mean improvements were substantially greater than the minimum clinically important difference of 2–3 points<sup>13</sup>
- Overall, patients and physicians perceived improvements in EDS after switching to solriamfetol or adding solriamfetol to ongoing medication
- Common adverse events were consistent with those previously reported for solriamfetol<sup>14-16</sup>

## References

- Pagal JF. *Am Fam Physician*. 2009;79:391-396.
- Thorpy MJ, Dauvilliers Y. *Sleep Med*. 2015;16:9-18.
- Gasa M, et al. *J Sleep Res*. 2013;22:389-397.
- Lal C, et al. *Ann Am Thorac Soc*. 2021;18:757-768.
- Gursahani H, et al. *Sleep*. 2022;45(suppl 1):A329.
- Sunos<sup>®</sup> (solriamfetol) tablets Prescribing Information. New York, NY, USA: Axsome Therapeutics; 2022.
- Sunos<sup>®</sup> (solriamfetol) tablets Summary of Product Characteristics. Malta: Axsome Malta; 2022.
- Sunos<sup>®</sup> (solriamfetol) tablets Summary of Product Characteristics. Kobenhavn S, Denmark. Almhals Pharma Netherlands; 2023.
- Winter Y, et al. *Sleep Med*. 2023;103:138-143.
- Winter Y, et al. Presented at the Annual Meeting of the Associated Professional Sleep Societies; June 3-7, 2023; Indianapolis, IN.
- Johns MW. *Sleep*. 1991;14:540-545.
- Johns M, Hocking B. *Sleep*. 1997;20:844-849.
- Patel S, et al. *Am J Respir Crit Care Med*. 2018;197:961-963.
- Malhotra A, et al. *Sleep*. 2020;43:zsz2220.
- Schweitzer PK, et al. *Am J Respir Crit Care Med*. 2019;199:1421-1431.
- Thorpy MJ, et al. *Ann Neurol*. 2019;85:359-370.

## Acknowledgments

The authors would like to thank the patients, study investigators, and study staff for their contributions to this research. This study was sponsored by Axsome Therapeutics, Inc., Jazz Pharmaceuticals, and Pharamanovia. Under the direction of the authors, Kelly Miller, MPH, of Peloton Advantage, LLC, an OPEN Health company, provided medical writing and editorial support for this poster, which was funded by Axsome Therapeutics, Inc.

## Disclosures

Y. Winter has received honoraria for educational presentations and consultations from Anville Therapeutics, Angelini Pharma, Bayer AG, Bial, Bioprojet Pharma, Bristol Myers Squibb, Eisai, Ethypharm GmbH, GW Pharmaceuticals, Idorsia Pharmaceuticals, Jazz Pharmaceuticals, LivaNova, Neuraxpharm, Novartis, and UCB Pharma.

L. Burghaus has nothing to disclose.  
G.M.L. Eglit is an employee of Axsome Therapeutics, Inc.  
S. Floam and G. Parks are employees of Axsome Therapeutics, Inc. and former employees of Jazz Pharmaceuticals.

## Introduction

- Excessive daytime sleepiness (EDS) is a core symptom of narcolepsy types 1 and 2<sup>1,2</sup>; EDS is also a common symptom of obstructive sleep apnea (OSA) that can persist in patients despite positive airway pressure therapy<sup>3,4</sup>
- Solriamfetol (Sunosi<sup>®</sup>) is a dopamine-norepinephrine reuptake inhibitor with agonistic properties at the trace amine-associated receptor 1 (TAAR1) and serotonin 1A (5-hydroxytryptamine 1A [5-HT1A]) receptors<sup>5</sup>; it is approved for use in adults in the United States, Canada, and select countries in Europe for the treatment of EDS associated with narcolepsy (75–150 mg/day) or OSA (37.5–150 mg/day)<sup>6-8</sup>
- Real-world evidence is limited on how physicians prescribe and initiate treatment with solriamfetol in patients with EDS associated with narcolepsy or OSA<sup>9</sup>; such data may help clinicians optimize patient care

## Key Findings

### Patients

- Pooled analysis included 71 (46%) patients who were prescribed solriamfetol for narcolepsy and 83 patients (54%) with OSA; baseline data for these 2 patient groups have been presented previously (Table 1)<sup>9,10</sup>


	Changeover (N=53)	Add-on (N=31)	New-to-Therapy (N=70)	Overall (N=154)
Age, mean (SD), years	39 (15)	38 (12)	49 (15)	43 (15)
Sex (female), n (%)	28 (53)	16 (52)	25 (36)	69 (45)
BMI, mean (SD), kg/m <sup>2</sup>	27.6 (5.8)	28.9 (5.7)	31.5 (6.4)	29.7 (6.3)
ESS score, mean (SD)	17.1 (3.3)	17.6 (3.1)	16.1 (3.1)	16.7 (3.2)
Comorbidities, <sup>a</sup> n (%)				
Obesity	14 (26)	13 (42)	31 (44)	58 (38)
Hypertension	10 (19)	9 (29)	30 (43)	49 (32)
Anxiety/depression	20 (38)	11 (35)	17 (24)	48 (31)
Diabetes type 2	7 (13)	7 (23)	15 (21)	29 (19)
Other sleep disorder	4 (8)	4 (13)	15 (21)	23 (15)

The present pooled analysis includes 71 patients with narcolepsy; previously published SURVEY analysis included 70 patients with narcolepsy.<sup>9</sup>  
BMI, body mass index; ESS, Epworth Sleepiness Scale; OSA, obstructive sleep apnea.  
<sup>a</sup>Comorbidities reported in ≥15% of the overall pooled population (N=154).

- The most common initiation strategy was changeover in patients with narcolepsy (n=44/71; 62%) and new-to-therapy in patients with OSA (n=62/83; 75%)
  - Solriamfetol was initiated as add-on therapy in 27% (19/71) of patients with narcolepsy, 14% (12/83) of patients with OSA, and 20% (31/154) overall
  - Patients most commonly switched to or added on solriamfetol when taking modafinil and/or pitolisant
- Most of the pooled group reported switching due to lack of efficacy (91%); most (89%) switched abruptly from prior medication
- Among patients with available data, the final solriamfetol dose was ≥150 mg/day in 46% (31/68) of patients with narcolepsy, 20% (16/82) of patients with OSA, and 31% (47/150) overall

## Efficacy

- ESS scores improved from baseline regardless of solriamfetol initiation strategy and across all etiologies (Figure 1)




- In the changeover group, ESS scores improved by 5.7, 4.7, 4.6, and 4.0 points in patients who switched to solriamfetol from modafinil (n=13), stimulants (n=3), pitolisant (n=16), or unknown medication (n=21), respectively (Figure 2A), while patients who added solriamfetol to pitolisant (n=13) or modafinil (n=3) improved by 4.4 and 3.3 points, respectively (Figure 2B)
- Across all etiologies and initiation strategies, mean improvements in ESS scores were substantially greater than the minimum clinically important difference of 2–3 points<sup>13</sup>

## Methods & Study Design


- SUNosi Real World Experience StudY (SURVEY) was a retrospective chart review among physicians in Germany who have prescribed solriamfetol to patients with EDS associated with narcolepsy or OSA
- Eligible patients were ≥18 years of age, had a diagnosis of EDS and OSA or narcolepsy, had reached a stable maintenance dose of solriamfetol, and had completed ≥6 weeks of treatment; patients who received solriamfetol during a clinical trial or early access program were excluded
- Solriamfetol initiation and titration strategies included: **changeover** (switched/switching from existing EDS medication[s]), **add-on** (added/adding to current EDS medication[s]), and **new-to-therapy** (no current/previous EDS medication)
- The present pooled analysis includes data from a total of 154 patients with OSA or narcolepsy from Germany
  - Initiation and titration strategies and Epworth Sleepiness Scale (ESS) scores are reported for each diagnosis and the pooled population to examine EDS as a symptom independent of etiology
  - Data related to solriamfetol dosing/titration, comorbidities, changes in ESS, patient- and physician-reported effectiveness of solriamfetol, and adverse events were summarized descriptively

**Figure 2. ESS Mean Improvement by (A) Changeover<sup>a</sup> and (B) Add-on<sup>b</sup> Medication in the Pooled Population**



- In the pooled population, 89% and 97% of patients in the changeover and add-on groups, respectively, reported improvement (“slightly improved” or “strongly improved”) in EDS; physician perceptions on EDS are presented in Figure 3

**Figure 3. Physician Perceptions of EDS Improvement**



## Safety

- Table 2 summarizes the treatment-emergent adverse events

	Changeover (N=53)	Add-on (N=31)	New-to-Therapy (N=70)	Overall (N=154)
Any TEAE, n (%)	19 (36)	11 (35)	18 (26)	48 (31)
Headache	5 (9)	3 (10)	5 (7)	13 (8)
Decreased appetite	5 (9)	1 (3)	4 (6)	10 (6)
Insomnia	3 (6)	1 (3)	5 (7)	9 (6)
Irritability	3 (6)	1 (3)	3 (4)	7 (5)
Other	2 (4)	2 (6)	2 (3)	6 (4)
Dizziness	1 (2)	3 (10)	1 (1)	5 (3)
Feeling jittery	1 (2)	2 (6)	2 (3)	5 (3)
Anxiety	3 (6)	0 (0)	0 (0)	3 (2)
Nausea	1 (2)	1 (3)	1 (1)	3 (2)
Abdominal pain	0 (0)	1 (3)	2 (3)	3 (2)

TEAE, treatment-emergent adverse event.  
<sup>a</sup>Reported in ≥2% of the overall pooled population (N=154).

- Safety data for the narcolepsy and OSA populations have been presented previously<sup>9,10</sup>
- Adverse events were consistent with those previously reported in clinical trials of solriamfetol in participants with narcolepsy and OSA<sup>14-16</sup>



Scan QR code or access  
<https://www.associatedprosleepsocieties.com/APSS2024>  
to view or download a PDF of this poster or access  
additional information and other Axsome  
Therapeutics presentations at APSS 2024.